FDA urges docs to report misleading drug ads

May 11, 2010 By MATTHEW PERRONE , AP Business Writer

(AP) -- The Food and Drug Administration said Tuesday it will begin asking doctors to keep an eye out for misleading drug advertisements as part of the agency's latest effort to police the pharmaceutical industry's multibillion-dollar marketing machine.

The agency's "bad ad program" urges doctors to report ads and sales pitches that violate FDA rules. Drug companies are legally required to present a balanced picture of a drug's benefits and risks in promotions, though critics charge that many TV and magazine ads fail to do so.

Currently the FDA relies on a few dozen staffers to review hundreds of pharmaceutical ads, brochures and presentations voluntarily submitted by companies or reported to the agency by drug industry personnel.

The agency issues warning letters to companies using misleading materials, but because of the volume of submissions those letters often aren't sent until months after the ad is released - and in some cases after the ad is no longer in circulation.

As part of its new program FDA will offer doctors training at medical conferences to help spot misleading ads. They can report advertising violations anonymously by e-mailing badad(at)fda.gov or calling 877-RX-DDMAC.

"The Bad Ad Program will help recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency," said Thomas Abrams, director of FDA's division.

Drugmakers spend about $20 billion per year to promote their products in various mediums, ranging from medical journal ads and information booths at conferences to multimillion dollar TV campaigns.

About $4 billion of industry spending goes toward patient-targeted advertisements. Some drug industry critics charge TV drug advertisements encourage over-prescribing of medications by emphasizing the benefits and minimizing the risks.

The FDA is also conducting a 2,000-person study to determine if the relaxing, upbeat images featured in TV drug ads distract consumers from warnings about the drugs' risks.

Explore further: FDA approves second vaccine against meningitis strain

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Google, Yahoo call for expanded online drug ads

Nov 12, 2009

(AP) -- Google, Yahoo and other Web companies joined the pharmaceutical industry Thursday in urging federal regulators to make it easier to pitch drugs in online advertisements.

Despite some benefit, drug ads can be harmful to your health

Nov 12, 2009

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize ...

Drug industry presses FDA to allow more online ads

Nov 11, 2009

(AP) -- As federal regulators take their first tentative steps toward policing the wild west of medical information online, pharmaceutical companies are pressing their case to market drugs via Google, Twitter ...

FDA Web site explains agency operations to public

Jan 12, 2010

(AP) -- The Food and Drug Administration is launching a new Web site explaining its operations to consumers as part of a broader effort to rebrand itself as a more accessible agency.

Online ad revenue up 2.6 pct in 4Q to $6.3 bln

Apr 08, 2010

(AP) -- Online advertising revenue grew by 2.6 percent in the fourth quarter, the first year-over-year increase in more than 12 months as companies became more comfortable with spending on marketing, according to report ...

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.